Price (delayed)
$1.59
Market cap
$2.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.85
Enterprise value
-$981,383
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment
There are no recent dividends present for SLRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.